SCHEMBL1508958

SCHEMBL1508958

CCOC(=O)C(C)(NC(=O)OC(C)(C)C)c1ccc(Cl)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.42
DGAT1 O75907 1/20 0.41
PTPRB P23467 1/20 0.40
RAB9A P51151 2/20 0.39
POLB P06746 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MAPT P10636 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
AAK1 Q2M2I8 4/20 0.37
GPR119 Q8TDV5 1/20 0.37
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
ABCB11 O95342 1/20 0.36
TSHR P16473 1/20 0.36
HTR2A P28223 1/20 0.36
PMP22 Q01453 1/20 0.36
PPARA Q07869 1/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2490507 0.85 ABCB11 (0.49) GAAPTPRBPOLBKDM4EMAPT
SCHEMBL7233451 0.80 PTPRB (0.45) PTPRBRAB9AKDM4EMAPTCYP1A2
SCHEMBL2925457 0.80 PTPRB (0.42) PTPRBKDM4EMAPTAAK1CYP1A2
SCHEMBL2490368 0.80 CNR2 (0.39) GAAPTPRBKDM4EMAPTAAK1
SCHEMBL29922800 0.79 DGAT1 (0.49) GAADGAT1RAB9APOLBKDM4E
SCHEMBL31247637 0.79 GAA (0.43) GAAAAK1KMT2AALDH1A1LMNA
SCHEMBL17796511 0.79 DGAT1 (0.49) GAADGAT1RAB9APOLBKDM4E
SCHEMBL1509032 0.79 KMT2A (0.44) GAAPTPRBRAB9AKDM4EMAPT
SCHEMBL14802200 0.78 KCNQ3 (0.45) GAARAB9APOLBMAPTTSHR
SCHEMBL19459161 0.78 DGAT1 (0.48) GAADGAT1RAB9APOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130172362-A1 Imidazothiazole Derivatives Having Proline Ring Structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-04 US disclosed
US-20130172362-A1 Imidazothiazole Derivatives Having Proline Ring Structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-04 US disclosed
US-20130172362-A1 Imidazothiazole Derivatives Having Proline Ring Structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-04 US disclosed
US-8404691-B2 Imidazothiazole derivatives having proline ring structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-03-26 US disclosed
US-8404691-B2 Imidazothiazole derivatives having proline ring structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-03-26 US disclosed
US-8404691-B2 Imidazothiazole derivatives having proline ring structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-03-26 US disclosed
EP-2298778-A1 IMIDAZOTHIAZOLE DERIVATIVE HAVING 4,7-DIAZASPIROÝ2.5¨OCTANE RING STRUCTURE Daiichi Sankyo Company, Limited (JP) 2011-03-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172362-A1 Imidazothiazole Derivatives Having Proline Ring Structure MDM2, TP53, TP53BP1 GAA 3514/4885DGAT1 3730/4885PTPRB 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.